MetaCap

Ocugen (OCGN) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SAB Biotherapeutics (SABS) has outperformed Ocugen (OCGN) over the past year, losing 28.9% versus a loss of 33.8%. Over five years, OCGN leads with a -88.1% price change compared with -97.3% for SABS. Ocugen is the larger company by market cap ($260.6 million vs $253.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OCGN-33.80%SABS-28.86%
+121%+37%-47%
Nov 21, 20251 yearNov 20, 2026
OCGN-90.05%SABS-97.45%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OCGN versus SABS key metrics
MetricOCGNSABS
Share price$0.7679$2.81
Market cap$260.55M$253.15M
1-day change+4.79%-3.44%
YTD return-43.12%-24.87%
1-year return-33.80%-28.86%
5-year return-88.09%-97.32%
EPS (TTM)$-0.20$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.41M$0
Revenue growth (YoY)+8.83%-100.00%
Net income (latest FY)$-67.85M$13.27M
Operating margin-1425.70%—
Net margin-1537.41%—
52-week high$2.73$5.15
52-week low$0.691$2.44
Distance from 52-week high-71.82%-45.44%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1484.84%+314.23%
Average volume7.34M633.60K
Shares outstanding339.31M90.09M
Employees11686
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Ocugen grew revenue faster in its latest fiscal year (+8.83% vs -100.00%).

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

OCGN vs SABS FAQ

Which is bigger, Ocugen or SAB Biotherapeutics?

Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $253.15M for SAB Biotherapeutics (SABS).

Which stock has performed better over the past year, OCGN or SABS?

SABS returned -28.86% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.

Are Ocugen and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons